Ayca Dundar

39PUBLICATIONS
227CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 18, 2026
Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

|Mar 25, 2026
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Emmanuel S Antonarakis, Qing Cao, Victoria Catharine

|Mar 12, 2026
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.

Charles Swanton, Alan Bryce, Allen L Cohn

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Dec 04, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Nicolas Sayegh, Ryon P Graf, Umang Swami

|May 02, 2025
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.

Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi

Pageof 7

Frequent Collaborators

8 joint publications

Emmanuel S Antonarakis

7 joint publications

Oliver Sartor

6 joint publications

Michael Morris

5 joint publications

Himisha Beltran